Pfizer Inc. Announced That Its Investigational Group B Streptococcus (Gbs) Vaccine Candidate, Gbs6 Or Pf-06760805, Received Breakthrough Therapy Designation From The Us Food And Drug Administration (Fda) For The Prevention Of Invasive Gbs Disease Due To The Vaccine Serotypes In Newborns And Young Infants By Active Immunization Of Their Mothers During Pregnancy.The Fda Decision Is Informed By The Interim Analysis Of A Placebo-Controlled Phase 2 Study (Nct03765073), Evaluating The Safety And Immunogenicity Of Gbs6 In Healthy Pregnant Women Aged 18 To 40 Years, Who Were Vaccinated During The Second Or Early Third Trimester Of Pregnancy. The Study Remains Ongoing, And Pfizer Will Publish Outcomes From This Clinical Trial When It Is Completed.
